share_log

Roth Capital Initiates Coverage On BioRestorative Therapies With Buy Rating, Announces Price Target of $15

Benzinga Real-time News ·  Dec 7, 2022 08:14

Roth Capital analyst Jonathan Aschoff initiates coverage on BioRestorative Therapies (NASDAQ:BRTX) with a Buy rating and announces Price Target of $15.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment